Momelotinib in myelofibrosis-Reference-Cited by-同舟云学术

Momelotinib in myelofibrosis

Published:2024-03-23 Issue:5 Volume:25 Page:521-528
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Bruzzese Antonella¹,Martino Enrica Antonia¹,Labanca Caterina¹,Mendicino Francesco¹,Lucia Eugenio¹,Olivito Virginia¹,Zimbo Annamaria¹²,Fragliasso Valentina³,Neri Antonino⁴,Morabito Fortunato⁵,Vigna Ernesto¹,Gentile Massimo¹⁶

Affiliation:

1. Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy

2. UOC Laboratorio Analisi Cliniche, Biomolecolari e Genetica, Azienda Ospedaliera Annunziata, Cosenza, Italy

3. Laboratorio di Ricerca Traslazionale Azienda USL-IRCSS Reggio Emilia, Emilia-Romagna, Italy

4. Scientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, EmiliaRomagna, Italy

5. Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy

6. Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy

Funder

Ministry of Health

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2024.2343780

Reference53 articles.

1. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

2. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

3. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

4. Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

5. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study